Phase 4 Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have active or frequent Ménière's Disease
- People aged between 25 and 85 years old, male or female
- People who are willing and able to take the study medication as directed and attend all required appointments
- People who can read and write in English in order to complete the consent process
Who may not be able to join:
- People who are pregnant (a urine pregnancy test will be required for women who could potentially become pregnant)
- People who have previously had surgery for Ménière's Disease
- People who have had a bad reaction or adverse response to the medication being used in this study
- People who have a medical condition or medical history that the trial doctor considers a concern (confirm with trial site)
- People who have psychosis
- People who have a neurological tumour (a growth in or around the nervous system)
- People who have any other medical reason that prevents them from being given the study medications (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hamid Djalilian, MD, University of California, Irvine
Phone: (800) 263-9547
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Subjective improvement of Meniere's Disease
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.